Literature DB >> 22593572

Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions.

Julianne Stack1, Andrew G Bowie.   

Abstract

Toll-like receptors (TLRs) have an anti-viral role in that they detect viruses, leading to cytokine and IFN induction, and as such are targeted by viruses for immune evasion. TLR4, although best known for its role in recognizing bacterial LPS, is also strongly implicated in the immune response to viruses. We previously showed that the poxviral protein A46 inhibits TLR4 signaling and interacts with Toll-IL-1 receptor (TIR) domain-containing proteins of the receptor complex. However the exact molecular mechanism whereby A46 disrupts TLR4 signaling remains to be established, and may yield insight into how the TLR4 complex functions, since viruses often optimally target key residues and motifs on host proteins for maximal efficiency. Here we show that A46 targets the BB loop motif of TIR proteins and thereby disrupts receptor:adaptor (TLR4:Mal and TLR4:TRAM), but not receptor:receptor (TLR4:TLR4) nor adaptor:adaptor (Mal:MyD88, TRAM:TRIF, and Mal:Mal) TIR interactions. The requirement for an intact BB loop for TIR adaptor interactions correlated with the protein:protein interfaces antagonized by A46. We previously discovered a peptide fragment derived from A46 termed VIPER (Viral Inhibitory Peptide of TLR4), which specifically inhibits TLR4 responses. Here we demonstrate that the region of A46 from which VIPER is derived represents the TLR4-specific inhibitory motif of the intact protein, and is essential for A46:TRAM interactions. This study provides the molecular basis for pathogen subversion of TLR4 signaling and clarifies the importance of TIR motif BB loops, which have been selected for viral antagonism, in the formation of the TLR4 complex.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593572      PMCID: PMC3391086          DOI: 10.1074/jbc.M112.349225

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Structures of the toll-like receptor family and its ligand complexes.

Authors:  Mi Sun Jin; Jie-Oh Lee
Journal:  Immunity       Date:  2008-08-15       Impact factor: 31.745

2.  MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages.

Authors:  Chong-Shan Shi; John H Kehrl
Journal:  J Biol Chem       Date:  2008-09-04       Impact factor: 5.157

3.  The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer.

Authors:  Tomas Nyman; Pål Stenmark; Susanne Flodin; Ida Johansson; Martin Hammarström; Pär Nordlund
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

4.  Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation.

Authors:  Martina Schröder; Marcin Baran; Andrew G Bowie
Journal:  EMBO J       Date:  2008-07-17       Impact factor: 11.598

5.  Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.

Authors:  Maria Loiarro; Federica Capolunghi; Nicola Fantò; Grazia Gallo; Silvia Campo; Brunilde Arseni; Rita Carsetti; Paolo Carminati; Rita De Santis; Vito Ruggiero; Claudio Sette
Journal:  J Leukoc Biol       Date:  2007-06-04       Impact factor: 4.962

6.  A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins.

Authors:  Ricardo Núñez Miguel; Joyce Wong; Julian F Westoll; Heather J Brooks; Luke A J O'Neill; Nicholas J Gay; Clare E Bryant; Tom P Monie
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

7.  Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection.

Authors:  Martha A Hutchens; Kathryn E Luker; Joanne Sonstein; Gabriel Núñez; Jeffrey L Curtis; Gary D Luker
Journal:  PLoS Pathog       Date:  2008-09-19       Impact factor: 6.823

8.  Inhibition of IkappaB kinase by vaccinia virus virulence factor B14.

Authors:  Ron A-J Chen; Grigory Ryzhakov; Samantha Cooray; Felix Randow; Geoffrey L Smith
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

9.  Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis.

Authors:  Stephen C Graham; Mohammad W Bahar; Samantha Cooray; Ron A-J Chen; Daniel M Whalen; Nicola G A Abrescia; David Alderton; Raymond J Owens; David I Stuart; Geoffrey L Smith; Jonathan M Grimes
Journal:  PLoS Pathog       Date:  2008-08-15       Impact factor: 6.823

Review 10.  Viral evasion and subversion of pattern-recognition receptor signalling.

Authors:  Andrew G Bowie; Leonie Unterholzner
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

View more
  22 in total

1.  Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling.

Authors:  Mark M Hughes; Peter Lavrencic; Rebecca C Coll; Thomas Ve; Dylan G Ryan; Niamh C Williams; Deepthi Menon; Ashley Mansell; Philip G Board; Mehdi Mobli; Bostjan Kobe; Luke A J O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

2.  Poxviral protein A52 stimulates p38 mitogen-activated protein kinase (MAPK) activation by causing tumor necrosis factor receptor-associated factor 6 (TRAF6) self-association leading to transforming growth factor β-activated kinase 1 (TAK1) recruitment.

Authors:  Julianne Stack; Tara P Hurst; Sinead M Flannery; Kiva Brennan; Sebastian Rupp; Shun-Ichiro Oda; Amir R Khan; Andrew G Bowie
Journal:  J Biol Chem       Date:  2013-10-10       Impact factor: 5.157

3.  Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

Authors:  Juan García-Arriaza; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

4.  TRAM is required for TLR2 endosomal signaling to type I IFN induction.

Authors:  Julianne Stack; Sarah L Doyle; Dympna J Connolly; Line S Reinert; Kate M O'Keeffe; Rachel M McLoughlin; Søren R Paludan; Andrew G Bowie
Journal:  J Immunol       Date:  2014-11-10       Impact factor: 5.422

5.  Exogenous heat shock protein HSP70 reduces response of human neuroblastoma cells to lipopolysaccharide.

Authors:  M M Yurinskaya; S Y Funikov; M B Evgen'ev; M G Vinokurov
Journal:  Dokl Biochem Biophys       Date:  2016-09-07       Impact factor: 0.788

6.  Encapsulated Hsp70 decreases endotoxin-induced production of ROS and TNFα in human phagocytes.

Authors:  M M Yurinskaya; O Yu Kochetkova; L I Shabarchina; O Yu Antonova; A V Suslikov; M B Evgen'ev; M G Vinokurov
Journal:  Cell Stress Chaperones       Date:  2016-10-26       Impact factor: 3.667

7.  Wogonin inhibits LPS-induced inflammatory responses in rat dorsal root ganglion neurons via inhibiting TLR4-MyD88-TAK1-mediated NF-κB and MAPK signaling pathway.

Authors:  Shibiao Chen; Jiangqin Xiong; Yanping Zhan; Weicheng Liu; Xiuhong Wang
Journal:  Cell Mol Neurobiol       Date:  2014-12-14       Impact factor: 5.046

8.  Inhibition of TLR4 signaling by TRAM-derived decoy peptides in vitro and in vivo.

Authors:  Wenji Piao; Stefanie N Vogel; Vladimir Y Toshchakov
Journal:  J Immunol       Date:  2013-01-23       Impact factor: 5.422

9.  Structure of vaccinia virus A46, an inhibitor of TLR4 signaling pathway, shows the conformation of VIPER motif.

Authors:  Yongwoon Kim; Hasup Lee; Lim Heo; Chaok Seok; Jungwoo Choe
Journal:  Protein Sci       Date:  2014-04-28       Impact factor: 6.725

10.  Characterization and structure of the vaccinia virus NF-κB antagonist A46.

Authors:  Sofiya Fedosyuk; Irina Grishkovskaya; Euripedes de Almeida Ribeiro; Tim Skern
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.